Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections | Zendy

Alok Singh | Zendy; Ritesh P. Thakare | Zendy; Pratiksha Karaulia | Zendy; Swetarka Das | Zendy; Isha Soni | Zendy; Manitosh Pandey | Zendy; Amit Kumar Pandey | Zendy; Sidharth Chopra | Zendy; Amitava Dasgupta | Zendy

Open Access

Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections

Author(s) -

Alok Singh,

Ritesh P. Thakare,

Pratiksha Karaulia,

Swetarka Das,

Isha Soni,

Manitosh Pandey,

Amit Kumar Pandey,

Sidharth Chopra,

Amitava Dasgupta

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx277

Subject(s) - microbiology and biotechnology , meropenem , mycobacterium fortuitum , ceftazidime , amikacin , imipenem , mycobacterium smegmatis , biology , pharmacology , mycobacterium , antibiotics , chemistry , mycobacterium tuberculosis , medicine , antibiotic resistance , tuberculosis , bacteria , genetics , pathology , pseudomonas aeruginosa

Novel drug discovery against non-tuberculous mycobacteria is beset with a large number of challenges including the existence of myriad innate drug resistance mechanisms as well as a lack of suitable animal models, which hinders effective translation. In order to identify molecules acting via novel mechanisms of action, we screened the Library of Pharmacologically Active Compounds against non-tuberculous mycobacteria to identify such compounds.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research